🔎 Trials Near Me

Почетна › Лимфом › Илиноис

Клинички испитувања за Лимфом во Илиноис

23 студии за Лимфом бараат учесници на локации во Илиноис.

Градови во Илиноис

Официјален текст на студијата (англиски)

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

  • Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT04234048

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT07015242

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • Lurie Children's Hospital-Chicago, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Се регрутираФаза 1/2
12 Months – 21 Years · Сите полови · Ажурирано 11.9.2026 · NCT04870944

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

  • Research Site, Chicago
Се регрутираФаза 3
Возраст од 18 до 18 · Сите полови · Ажурирано 8.9.2026 · NCT07509151

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • University of Illinois Cancer Center, Chicago
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT06624085

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • City of Hope - Chicago, Zion
Се регрутираФаза 1/2
Возраст 12 и постари · Сите полови · Ажурирано 3.9.2026 · NCT04588922

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

  • University of Chicago, Chicago
  • Northwestern University, Evanston
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 28.8.2026 · NCT07284433

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

  • University of Chicago Medical Center, Chicago
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 19.8.2026 · NCT04104776

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

  • The David and Etta Jonas Center for Cellular Therapy, Chicago
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT06528301

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Northwestern, Chicago
  • University of Chicago, Chicago
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 4.8.2026 · NCT07188558

Mosaic Trial for Stem Cell Transplant Recipients

  • Northwestern University Feinberg School of Medicine, Chicago
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 3.8.2026 · NCT06960993

DALY II USA/ MB-CART2019.1 for DLBCL

  • Robert H Lurie Cancer Center, Chicago
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 13.7.2026 · NCT04792489

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

  • Call for Information (Investigational Site 0024), Chicago
Се регрутираФаза 1/2
6 Months – 17 Years · Сите полови · Ажурирано 6.7.2026 · NCT02332668

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • Northwestern University, Chicago
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 2.7.2026 · NCT05131022

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Lurie Children's Hospital-Chicago, Chicago
  • Advocate Children's Hospital-Oak Lawn, Oak Lawn
  • Saint Jude Midwest Affiliate, Peoria
Се регрутираНабљудувачка студија
Сите возрасти · Сите полови · Ажурирано 18.5.2026 · NCT01790152

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • Northwestern Memorial Hospital, Chicago
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 16.4.2026 · NCT03328078

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • University of Illinois at Chicago Cancer Center, Chicago
Се регрутираФаза 1/2
Возраст од 12 до 95 · Сите полови · Ажурирано 15.4.2026 · NCT04329728

A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma

  • City of Hope Chicago, Zion
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 27.3.2026 · NCT06915246

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  • The University of Chicago Medical Center, Chicago
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 20.3.2026 · NCT04830137

CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 4.3.2026 · NCT07294677

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

  • University of Chicago Comprehensive Cancer Center, Chicago
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 20.2.2026 · NCT05745285

Avo In R/R And Previously Untreated MCL

  • University of Chicago Medical Center, Chicago
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 21.1.2026 · NCT04855695

Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial

  • OSF Saint Anthony's Health Center, Alton
Се регрутираФаза 3Добредојдени се здрави волонтери
Возраст 18 и постари · Сите полови · Ажурирано 13.1.2026 · NCT05006482

Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.